Actively Recruiting
Evaluating Anti-Obesity Medications 6 Months After Metabolic Surgery
Led by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Updated on 2026-01-27
60
Participants Needed
1
Research Sites
75 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This clinical trial aims to evaluate the weight-loss efficacy and safety of efsubaglutide alfa in patients who remain obese 6 months after metabolic surgery.
CONDITIONS
Official Title
Evaluating Anti-Obesity Medications 6 Months After Metabolic Surgery
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 6 months after metabolic surgery
- Age between 18 and 55 years
- Body Mass Index (BMI) of 28 kg/m² or higher
- Voluntarily signed informed consent and agrees to follow all study requirements
You will not qualify if you...
- Allergy or suspected allergy to the study drug or its components
- Use of GLP-1R agonists within 3 months before screening
- Use of weight-affecting medications or herbal supplements within 3 months before screening
- Use of weight-loss medications within 3 months before screening or current use
- Participation in other clinical trials involving investigational drugs within 3 months before screening
- History of depression or severe psychiatric disorders such as schizophrenia or bipolar disorder
- Uncontrolled hypertension despite medication, with blood pressure over 160/100 mmHg
- History of cancer
- History of serious heart conditions including heart attack, unstable angina, or severe arrhythmia
- Stroke or transient ischemic attack within 6 months before screening
- History or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2A or 2B
- History of pancreatitis or pancreatic injury
- Limb deformities or amputations that prevent accurate body measurements
- Major surgery, severe trauma, or infection within 1 month before screening
- History of suicidal tendencies or attempts
- Planned surgery during the study period
- Positive tests for HIV, hepatitis B or C, or syphilis
- History of alcohol abuse within 1 month before screening
- Significant abnormalities on ECG such as severe arrhythmias or conduction blocks
- Risk factors for torsades de pointes, including family history or certain medications
- Blood donation or loss exceeding 400 mL within 3 months before screening or low hemoglobin levels
- Any other factors deemed by the investigator to affect study safety or results
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China
Actively Recruiting
Research Team
W
wenhuan Feng
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here